Danazol in Hemophilia

R Ambríz
In: JAMA: The Journal of the American Medical Association · 1985 · vol. 254(6) , pp. 754 · doi:10.1001/jama.1985.03360060052015 · PMID:4009909 · W2088711815
letter OA: closed CC0
View on OpenAlex View on PubMed View at publisher

Abstract

To the Editor.— In a recent article Garewal et al1demonstrated that danazol, an attenuated androgen, given at a dose of 600 mg daily for eight to 14 weeks, is not useful in the treatment of factor VIII—deficient and factor IX—deficient hemophilic patients. Some hemophilic patients experienced abnormal bleeding with danazol—a problem attributed to increased fibrinolysis.1,2 Subjects and Methods.— In 1984, we undertook a two-week trial of danazol in 800-mg/day oral doses, in addition to aminocaproic acid in 10-g/day oral doses as an inhibitor of fibrinolysis. The subjects were 20 adults with hemophilia and no factor VIII inhibitor, nor evidence of active bleeding. Eighteen cases had moderate to mild hemophilia A (3.2% to 10% of factor VIII), and two cases had moderate hemophilia B (3% and 4.2% of factor IX). Two of the 20 patients showed an increase in deficient factor levels: one with an initial factor VIII

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (5)

Source provenance

openalex
last seen: 2026-05-11T04:44:38.335450+00:00
unpaywall
last seen: 2026-06-16T06:25:30.133384+00:00
License: CC0 · commercial use OK